Board of Directors

Chairman of the Board of Directors

Over the course of his career, Dr. Pomerantz led the development of 12 infectious disease drugs that have been approved and launched worldwide, and established an outstanding track record in licensing and acquisitions. Following an academic career, most recently as an endowed, tenured Professor of Medicine, Biochemistry and Molecular Pharmacology, and Chief of Infectious Diseases at Thomas Jefferson University and Medical School, he joined Johnson & Johnson’s Tibotec Pharmaceuticals unit as President. He subsequently moved to Merck, where he served as Global Head of the Infectious Diseases Franchise and Senior Vice President at Merck Research Labs, and Worldwide Head of Licensing and Acquisitions, Senior Vice President at Merck & Co. Following Merck, he become President, CEO and Chairman of the Board of Seres Therapeutics, where he continues to serve as Chairman. He joined Contrafect in 2014 as Vice Chairman of the Board of Directors and he currently serves as President, CEO and Chairman. He is also on several other boards including Intec Pharma, Inc. Dr. Pomerantz holds a BA in Biochemistry from Johns Hopkins University and an MD from the Johns Hopkins University School of Medicine. He did his medical post-graduate training at the Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), where he did a subspecialty fellowship in Infectious Diseases. Dr. Pomerantz was also the Chief Resident at MGH. He is board certified in both Internal Medicine and Infectious Diseases. He did post-doctoral training at the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Dr. David Baltimore, in molecular retrovirology.  

Board Director

Dr. Trency Gu is the Managing Director at Sequoia in their Shanghai Office, focusing on healthcare investments, with a focus on biotech, molecular diagnostics and precision medicine. Prior to joining Sequoia, she worked as an Associate at OrbiMed’s Asia team, covering healthcare and life sciences investments. Prior, Dr. Gu worked as a Project Manager at Eli Lilly Global External Research and Development Center in Shanghai, responsible for scouting, collaboration and partnership activities. She also worked at Shanghai Genomics, a biotech company on innovative drug discovery and development, as a Director for Development Planning. Dr. Gu has a B.S. with double majors in Biotechnology and English, and a Ph.D. in Biochemistry and Molecular Biology, both from Shanghai Jiao Tong University.

Board Director

Mark J. Gilbert, Chief Medical Officer joined Juno in March 2014. Prior to joining Juno, Dr. Gilbert served as an interim CMO or consultant in strategic drug development and portfolio management in medical oncology for several US biotech and pharmaceutical companies. Previously, Dr. Gilbert served as Vice President and Head Global Clinical Development, Therapeutic Area Oncology, at Bayer Schering Pharmaceuticals. Prior to Bayer Schering, he held several executive positions with Berlex Pharmaceuticals and its parent company Schering, AG, mostly as Vice President and Head of Global Medical Development Group, Oncology. Dr. Gilbert joined Berlex from Immunex, where his responsibilities included development and medical affairs for Leukine and Mitoxantrone in hematology, oncology, Crohn’s disease, and multiple sclerosis. Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and his M.D. from the University of Iowa Medical School and trained in internal medicine, infectious disease, and medical oncology at the University of California, San Francisco, and the University of Washington, respectively. Prior to his executive positions in biotech and oncology companies, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington and trained in the laboratory of Dr. Phil Greenberg, one of Juno’s scientific co-founders.

Board Director, CEO

Lanny co-founded Silicon Therapeutics in 2016. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He started his career on Wall Street with Deutsche Bank Securities where he focused on Healthcare M&A and financings and was most recently a Venture Partner at Chengwei. He received his Bachelors of Science in Economics from Trinity College in Hartford, CT.

Board Director

Dr. Wang is the CEO of Harbour BioMed (HBM). Before establishing HBM, Dr. Wang served as the Head of China Research and Development Center and the Head of Translational Medicine for Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets.Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women’s Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’ s laboratory at the Harvard School of Public Health. Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.